

# Synairgen PLC

16:30 22 Jun 2018

## Synairgen's lead drug well tolerated so far in phase II trial

Interim safety data from the phase II trial of Synairgen plc's (LON:SNG) lead drug, SNG001, has shown it is being well tolerated.

Researchers are investigating whether the inhaled interferon beta treatment can better protect sufferers of chronic obstructive pulmonary disease (COPD) from the exacerbating effects of illnesses such as flu and the common cold.

### Part two gets thumbs-up

The mid-stage trial, called SG015, is taking place in two parts. The initial stage involves dosing ten people who have no evidence of viral infection to examine levels of antiviral biomarkers in response to the drug.

**WATCH:** Synairgen says its drug well tolerated in phase II trial

The aim is to assess whether SNG001 boosts antiviral defence mechanisms in the lung in the absence of a respiratory virus. Completion of the first stage is expected by the end of March.

Phase-two is designed to measure what Synairgen describes as "efficacy endpoints" and biomarker levels in patients with a respiratory virus.

A total of 80 patients will take part, receiving either SNG001 or a placebo that has no medical impact on the person receiving it.

As a result of Friday's positive safety data, the Drug Safety Monitoring Committee has given Synairgen the thumbs-up to go ahead with the second part of the trial, which is scheduled to cover the 2018/19 winter cold virus season.

### 'Reassuring' safety data

"COPD is a very severe disease and it is reassuring to establish that SNG001 is well tolerated in these patients," said Synairgen chief executive Richard Marsden.

"We look forward to seeing the biomarker analysis, which is due in the near term to see whether SNG001 has switched on the antiviral defence mechanisms.

"Changes in biomarkers translated into clinical benefit in Phase II trials in asthma. Therefore, if we see similar biomarker changes in this study, it will greatly increase our confidence in the potential of SNG001 in COPD, where colds and flu can cause more severe symptoms than in asthma."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

**Price:** 44

**Market Cap:** £65.75 m

### 1 Year Share Price Graph



May 2019 December 2019 May 2020

### Share Information

**Code:** SNG

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	81	5.5

**Sector:** Pharma & Biotech

**Website:** [www.synairgen.com](http://www.synairgen.com)

### Company Synopsis:

Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. &nbsp;

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).